- Home
- BRNS vs XGN Comparison
BRNS vs XGN Comparison
Compare BRNS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- XGN
- Stock Information
- Founded
- BRNS 2016
- XGN 2002
- Country
- BRNS United Kingdom
- XGN United States
- Employees
- BRNS N/A
- XGN N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- XGN Medical Specialities
- Sector
- BRNS Health Care
- XGN Health Care
- Exchange
- BRNS Nasdaq
- XGN Nasdaq
- Market Cap
- BRNS 48.3M
- XGN 138.3M
- IPO Year
- BRNS 2021
- XGN 2019
- Fundamental
- Price
- BRNS $1.05
- XGN $9.31
- Analyst Decision
- BRNS Strong Buy
- XGN Strong Buy
- Analyst Count
- BRNS 1
- XGN 5
- Target Price
- BRNS $3.00
- XGN $12.40
- AVG Volume (30 Days)
- BRNS 37.7K
- XGN 210.4K
- Earning Date
- BRNS 11-05-2025
- XGN 11-11-2025
- Dividend Yield
- BRNS N/A
- XGN N/A
- EPS Growth
- BRNS N/A
- XGN N/A
- EPS
- BRNS N/A
- XGN N/A
- Revenue
- BRNS $14,969,000.00
- XGN $58,862,000.00
- Revenue This Year
- BRNS N/A
- XGN $22.09
- Revenue Next Year
- BRNS N/A
- XGN $13.62
- P/E Ratio
- BRNS N/A
- XGN N/A
- Revenue Growth
- BRNS 1766.46
- XGN 3.89
- 52 Week Low
- BRNS $0.64
- XGN $2.38
- 52 Week High
- BRNS $2.92
- XGN $10.34
- Technical
- Relative Strength Index (RSI)
- BRNS 40.11
- XGN 47.62
- Support Level
- BRNS $1.08
- XGN $9.55
- Resistance Level
- BRNS $1.20
- XGN $10.28
- Average True Range (ATR)
- BRNS 0.09
- XGN 0.39
- MACD
- BRNS -0.01
- XGN -0.11
- Stochastic Oscillator
- BRNS 0.00
- XGN 11.81
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.